Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPEPLD | Q6IQ20 | 6/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | RAF1 | P04049 | 2/20 | 0.31 |
| ▸ | BRAF | P15056 | 2/20 | 0.31 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19686895 | 0.88 | ATR (0.33) | PIK3CAMTORPIK3R1POLBCREBBP | |
| SCHEMBL19686896 | 0.77 | IDH1 (0.42) | PIK3CAALDH1A1POLBHPGDIDH1 | |
| SCHEMBL20153241 | 0.77 | RAF1 (0.35) | NAPEPLDPIK3CAALDH1A1CREBBPIDH1 | |
| SCHEMBL20399551 | 0.77 | KMT2A (0.46) | NAPEPLDALDH1A1HPGDHSD17B10PKM | |
| SCHEMBL21143733 | 0.77 | PIK3CA (0.41) | PIK3CAMTORALDH1A1HSD17B10PKM | |
| SCHEMBL21143805 | 0.76 | PIK3CB (0.33) | NAPEPLDPIK3CAMTORALDH1A1POLB | |
| SCHEMBL20399778 | 0.76 | RAF1 (0.39) | NAPEPLDPIK3CAMTORPKMCREBBP | |
| SCHEMBL19686424 | 0.74 | CHRM3 (0.41) | PIK3CAALDH1A1POLBHPGDIDH1 | |
| SCHEMBL21144115 | 0.72 | ADORA2A (0.35) | NAPEPLDCREBBPGBA1 | |
| SCHEMBL21144188 | 0.72 | IDH1 (0.33) | IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380571-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS INC (US) | 2021-12-09 | — | — | US | disclosed |
| EP-3571193-B1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS INC (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10717728-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190352293-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-11-21 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-10351553-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2018-08-02 | — | — | US | disclosed |
| WO-2018136917-A1 | POTASSIUM CHANNEL MODULATORS | CADENT THERAPEUTICS, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-9975886-B1 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2018-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | NAPEPLD 1989/4885PIK3CA 1182/4885MTOR 1488/4885 |
| US-20210380571-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | NAPEPLD 2285/4885PIK3CA 1682/4885MTOR 2274/4885 |
| US-10717728-B2 | Potassium channel modulators | KCNJ2, KCNQ2, KCNJ1 | NAPEPLD 1675/4885PIK3CA 1117/4885MTOR 1751/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | NAPEPLD 1989/4885PIK3CA 1182/4885MTOR 1488/4885 |
| US-20190352293-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | NAPEPLD 2285/4885PIK3CA 1682/4885MTOR 2274/4885 |
| US-20180215746-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNK10, KCNJ1 | NAPEPLD 2285/4885PIK3CA 1682/4885MTOR 2274/4885 |
| US-10351553-B2 | Potassium channel modulators | KCNN2, KCNN1, KCNN3 | NAPEPLD 1970/4885PIK3CA 1148/4885MTOR 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.